Skip to main content

Table 1 Demographic data of Multiple sclerosis patients and healthy control subjects

From: Dysregulation of lysophosphatidic acids in multiple sclerosis and autoimmune encephalomyelitis

  Multiple sclerosis patients   Healthy controls
  Male Female     
  MS 1st course RRMS stable RRMS acute relapse SPMS or PPMS MS 1st course RRMS stable RRMS acute relapse SPMS or PPMS Total number (m/f) Male Female Total
Number (all treatments) 8 16 4 3 12 39 18 2 102 (35/67) 118 183 301
Age (Years mean ± SD) 38.2 ± 7.5 35.5 ± 0.4 33.9 ± 7.0 43.6 ± 18.1 31.6 ± 9.1 34.3 ± 8.9 37.2 ± 10.9 49.3 ± 11.0 35.5 ± 9.7 25.0 ± 6.1 24.9 ± 6.1 25.0 ± 6.1
Years since diagnosis 0.1 ± 0.4 7.6 ± 6.1 2.1 ± 1.8 5.7 ± 4.7 0.8 ± 0.2 7.4 ± 5.9 6.7 ± 5.3 1.1 ± 1.3 5.6 ± 5.7    
Relapse prophylaxis Number of patients No drug 6 3 1 1 11 6 10 1 39    
Interferon 0 6 2 0 0 11 5 1 25    
Fingolimod 0 3 0 1 0 5 1 0 10    
Natalizumab 0 4 0 0 0 15 0 0 19    
Other 2 0 1 1 1 2 2 0 9    
\